Aripiprazole Tablet
Product Images NDC 43547-305

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 43547-305). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare U.s., Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2f5cad93-figure-02 (2f5cad93 Figure 01)

FDA Label Image

2f5cad93-figure-03 (2f5cad93 Figure 02)

The text describes the effect of different drugs on aripiprazole and provides data on the fold change and 90% CI of PK Avipiprazole. It includes the class of drugs such as CYP3A4 inhibitors, nmns inhibitors and CYP3AA inducers along with specific drugs and their corresponding fold change values. The data presented could be useful in understanding the impact of co-administering aripiprazole with other drugs.*

FDA Label Image

2f5cad93-figure-04 (2f5cad93 Figure 03)

This text provides information on the effect of different drugs on the pharmacokinetics of aripiprazole. It includes data on fold changes and 90% confidence intervals for dehydro-aripiprazole levels when co-administered with drugs that inhibit or induce CYP enzymes or block gastric acid. The text also mentions the effect of valproate and lorazepam on aripiprazole.*

FDA Label Image

C:\users\ra\desktop\aripiprazole-plr\figure 4.png (2f5cad93 Figure 04)

This text seems to be a table showing the effect of Aripiprazole on the AUC and Cmax of other drugs such as omeprazole, valproate, lorazepam, venlafaxine, and others. The table displays the fold change and 90% confidence interval. No further information or context is available.*

FDA Label Image

C:\users\ra\desktop\aripiprazole-plr\figure 5.png (2f5cad93 Figure 05)

This text appears to be a table with headings for "Special Populations", "Age", "Hepatic impairment", and "Renal impairment". The table contains various levels of impairment and related rates. The last section includes a graph with "Aripiprazole Fold Change and 30% CI" headings. It is unclear what the graph represents without additional information.*

FDA Label Image

C:\users\ra\desktop\aripiprazole-plr\figure 6.png (2f5cad93 Figure 06)

FDA Label Image

2f5cad93-figure-08 (2f5cad93 Figure 07)

FDA Label Image

2f5cad93-figure-09 (2f5cad93 Figure 08)

FDA Label Image

C:\users\ra\desktop\3.jpg (Arpiprazole 10mg 100count)

FDA Label Image

C:\users\ra\desktop\4.jpg (Arpiprazole 15mg 100count)

This is a package label for a medication called Aripiprazole Tablets, USP manufactured by Zrejan Hushsi Phamceuta Co. L in Xangan, Zrefang, China. The storage instructions indicate that the medicine should be stored in a closed container at room temperature between 20°C and 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F). The label also lists a distributor named Soka et US, LIC based in Somaret, NJ 06675, USA.*

FDA Label Image

C:\users\ra\desktop\5.jpg (Arpiprazole 20mg 100count)

FDA Label Image

C:\users\ra\desktop\1.jpg (Arpiprazole 2mg 100count)

FDA Label Image

C:\users\ra\desktop\6.jpg (Arpiprazole 30mg 100count)

FDA Label Image

C:\users\ra\desktop\2.jpg (Arpiprazole 5mg 100count)

FDA Label Image

C:\users\ra\desktop\aripiprazole-plr\structure.jpg (Structure)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.